Evaluating Survival Outcomes and Treatment Recommendations in Resectable Gastric Cancer

Overview

Journal Sci Rep

Date 2025 Jan 22

PMID 39843914

Authors

Saad Sabbagh

Iktej Singh Jabbal

Maria Herran

Mohamed Mohanna

Sindu Iska

Mira Itani

Barbara Dominguez

Kaylee Sarna

Zeina Nahleh

Arun Nagarajan

Affiliations

Soon will be listed here.

Abstract

No consensus exists on the optimal therapy for resectable gastric cancer (GC) and gastroesophageal junction (GEJ) tumors, including the effectiveness of chemoradiotherapy versus perioperative chemotherapy (PC). Our study aimed to compare overall survival (OS) outcomes associated with the recommended treatment modalities for GC and GEJ tumors and evaluate treatment trends from 2010 to 2020. A national registry cohort identified patients with ≥ cT2 nonmetastatic GC and GEJ cancer. Treatment modalities were classified as neoadjuvant chemotherapy (NC), neoadjuvant chemoradiotherapy (NCR), PC, adjuvant chemotherapy (AC), and adjuvant chemoradiation (ACR). Kaplan-Meier curve and multivariable Cox regression models evaluated factors associated with OS. A cohort of 7665 patients were included. Patients who received PC had the highest OS (median 86.80 months, 95% CI 73.40-NE), while chemoradiotherapy in the neoadjuvant and adjuvant settings had worse OS than PC and NC (NCR median 47.15 months, 95% CI 44.58-52.27, and ACR median 52.67 months, 95%CI 42.78-63.93). The Cox proportional hazards model showed that NCR and NC had worse survival than PC (HR 1.74, 95% CI 1.50-2.02, p < 0.001 and HR 1.26, 95% CI 1.10-1.44, p = 0.0008, respectively). Additionally, the most utilized modality during 2020 was NC (35.8%), followed by PC (28.0%) and NCR (24.9%). The utilization of PC and NC had the most substantial rise between 2010 and 2020, increasing by 11.0%. The study demonstrates the association of PC with improved OS outcomes for nonmetastatic GC and GEJ tumors. Therapies combining radiation with chemotherapy and extended lymph node dissection correlated with a worse prognosis compared to PC and NC. Despite the association with improved outcomes, national data reveals low utilization rates for PC.

References

Hoeppner J, Lordick F, Brunner T, Glatz T, Bronsert P, Rothling N . ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer. 2016; 16:503. PMC: 4952147. DOI: 10.1186/s12885-016-2564-y. View

Kang Y, Yook J, Park Y, Lee J, Kim Y, Kim J . PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. J Clin Oncol. 2021; 39(26):2903-2913. PMC: 8425847. DOI: 10.1200/JCO.20.02914. View

Ychou M, Boige V, Pignon J, Conroy T, Bouche O, Lebreton G . Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011; 29(13):1715-21. DOI: 10.1200/JCO.2010.33.0597. View

Lee J, Lim D, Kim S, Park S, Park J, Park Y . Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2011; 30(3):268-73. DOI: 10.1200/JCO.2011.39.1953. View

DAngelica M, Gonen M, Brennan M, Turnbull A, Bains M, Karpeh M . Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004; 240(5):808-16. PMC: 1356486. DOI: 10.1097/01.sla.0000143245.28656.15. View

Chen J, Guo Y, Fang M, Yuan Y, Zhu Y, Xin Y . Neoadjuvant chemoradiotherapy for resectable gastric cancer: A meta-analysis. Front Oncol. 2022; 12:927119. PMC: 9388908. DOI: 10.3389/fonc.2022.927119. View

Macdonald J, Smalley S, Benedetti J, Hundahl S, Estes N, STEMMERMANN G . Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001; 345(10):725-30. DOI: 10.1056/NEJMoa010187. View

Cunningham D, Allum W, Stenning S, Thompson J, van de Velde C, Nicolson M . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355(1):11-20. DOI: 10.1056/NEJMoa055531. View

Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G . Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022; 33(10):1005-1020. DOI: 10.1016/j.annonc.2022.07.004. View

10.

van Hagen P, Hulshof M, van Lanschot J, Steyerberg E, van Berge Henegouwen M, Wijnhoven B . Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366(22):2074-84. DOI: 10.1056/NEJMoa1112088. View

11.

Thrift A, Wenker T, El-Serag H . Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. 2023; 20(5):338-349. DOI: 10.1038/s41571-023-00747-0. View

12.

Zhu Y, Chen J, Sun X, Lou Y, Fang M, Zhou F . Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for locally advanced gastric cancer: a systematic review and meta-analysis. Front Oncol. 2023; 13:1177557. PMC: 10203550. DOI: 10.3389/fonc.2023.1177557. View

13.

Choi M, Ishizawa S, Kraemer D, Sasson A, Feinberg E . Perioperative chemotherapy versus adjuvant chemotherapy strategies in resectable gastric and gastroesophageal cancer: A Markov decision analysis. Eur J Surg Oncol. 2021; 48(2):403-410. DOI: 10.1016/j.ejso.2021.08.012. View

14.

Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z . Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label,.... Lancet Oncol. 2021; 22(8):1081-1092. DOI: 10.1016/S1470-2045(21)00297-7. View

15.

Bang Y, Kim Y, Yang H, Chung H, Park Y, Lee K . Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012; 379(9813):315-21. DOI: 10.1016/S0140-6736(11)61873-4. View

16.

Morgan E, Arnold M, Camargo M, Gini A, Kunzmann A, Matsuda T . The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: A population-based modelling study. EClinicalMedicine. 2022; 47:101404. PMC: 9046108. DOI: 10.1016/j.eclinm.2022.101404. View

17.

Al-Batran S, Homann N, Pauligk C, Goetze T, Meiler J, Kasper S . Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma.... Lancet. 2019; 393(10184):1948-1957. DOI: 10.1016/S0140-6736(18)32557-1. View

18.

Stahl M, Walz M, Riera-Knorrenschild J, Stuschke M, Sandermann A, Bitzer M . Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial. Eur J Cancer. 2017; 81:183-190. DOI: 10.1016/j.ejca.2017.04.027. View